US › Healthcare

DiaMedica Therapeutics Inc (DMAC)

US · Healthcare · Biotechnology

$7.57-5.85%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-10.1M

EPS

$-0.19

EPS estimate

$-0.19

EPS came in at -0.19 against a street estimate of -0.19 — a beat of 0.0%.

Key statistics

Market cap

$421.7M

Forward P/E

0.0

P/B

10.95

Book value

$0.71

EPS (TTM)

$-0.69

52-week high

$10.42

52-week low

$5.25

50-day MA

$7.09

200-day MA

$7.09

Beta

0.91

Analyst view

Analysts rate DiaMedica Therapeutics Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $15.50.

Shareholding

Insiders

27.83%

Institutions

40.92%

Largest institutional holders

Fund	Stake
Cooperman Leon G	6.40%
BlackRock Inc	4.18%
Geode Capital Management, LLC	1.66%
PARAGON Assoc & PARAGON Assoc II JV	1.62%
Millennium Management LLC	1.57%
State Street Corp	1.20%
Bleichroeder LP	0.71%
Vanguard Capital Management, LLC	0.66%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for DiaMedica Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.